With a US$1bn acquisition of Canadian Inversago Pharma, Novo Nordisk A/S fiights to maintain its dominant position in the booming weight loss drug market.
Lipid, nutrition and frozen bakery specialist Allianza Team puts £900,500 into pre-Series A financing of microbial palm oil producer Clean Food Group Ltd.
https://european-biotechnology.com/wp-content/uploads/2024/04/cellular_oil-4022602_1280.jpeg8521280Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2023-08-08 10:38:592024-07-09 14:41:11Alianza Team invests in microbial oil maker Clean Food Group
A Dutch-German team of researchers has found out that the amount of not degradable plastics is lower than estimated but that they persist for longer than previously assumed.
Researchers at the Karlsruhe Institute of Technology (KIT) have transformed enzymes into a new form: as foams, the biocatalysts prove to be extremely stable and active.
https://european-biotechnology.com/wp-content/uploads/2024/04/Bildschirmfoto_2023-08-09_um_04.46.58.png8221766Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2023-08-03 08:41:002024-07-09 15:11:45Enzyme foams morer active and stable
LSE-listed PureTech Health plc hat been granted p to US$11.4m from U.S. Department of Defense to advance LYT-300 to treat Fragile X-associated tremor/ataxia syndrome.
TG Therapeutics will receive US$140m upfront from German Neuraxpharm for Ex-US commercialisation rights of its deglycosylated anti-CD20 antibody ublituximab-xiiy.
https://european-biotechnology.com/wp-content/uploads/2024/04/Neuraxapharm.jpg4451440Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2023-08-01 16:10:462024-07-09 15:06:53Neuraxpharm pays US$650m for MS drug commercialisation
Novo Nordisk takes over Inversago Pharma Inc.
Latest NewsWith a US$1bn acquisition of Canadian Inversago Pharma, Novo Nordisk A/S fiights to maintain its dominant position in the booming weight loss drug market.
Promising viral gene therapy for genetic kidney disease
Latest NewsBritish researchers have proven that a new gene can prevent progression of hereditary kidney damage in mice.
Alianza Team invests in microbial oil maker Clean Food Group
Latest NewsLipid, nutrition and frozen bakery specialist Allianza Team puts £900,500 into pre-Series A financing of microbial palm oil producer Clean Food Group Ltd.
More marine plastics than expected
Latest NewsA Dutch-German team of researchers has found out that the amount of not degradable plastics is lower than estimated but that they persist for longer than previously assumed.
ViroCell Biologics appoints new CFO
AppointmentsViroCell Biologics, based in London, Dublin and New York, has appointed Brian Collins as Chief Financials Officer.
Sygnature Discovery Ltd acquires leading Canadian CRO
Latest NewsBritish drug discovery specialist Sygnature Discovery Ltd has taken over Canadian NuChem Sciences Inc., one of North Americas largest discovery CROs
Enzyme foams morer active and stable
Latest NewsResearchers at the Karlsruhe Institute of Technology (KIT) have transformed enzymes into a new form: as foams, the biocatalysts prove to be extremely stable and active.
Bavarian Nordic A/S bags US$120m for smallpox vaccine
Latest NewsBavarian Nordic A/S will get US$120m from a contract for the manufacturing of smallpox and mpox vaccine from the US government.
PureTech Health gets US$11.4m to advance LYT-300
Latest NewsLSE-listed PureTech Health plc hat been granted p to US$11.4m from U.S. Department of Defense to advance LYT-300 to treat Fragile X-associated tremor/ataxia syndrome.
Neuraxpharm pays US$650m for MS drug commercialisation
Latest NewsTG Therapeutics will receive US$140m upfront from German Neuraxpharm for Ex-US commercialisation rights of its deglycosylated anti-CD20 antibody ublituximab-xiiy.